Carlo Nobile
Research Subjects
Carlo Nobile has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Michelucci
Neurology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
30 shared publications Pasquale Striano
Muscular and Neurodegenerative Disease Unit, Institute "G. Gaslini," University of Genova, Italy
13 shared publicationsSalvatore Striano
Department of Neurological Sciences, Federico II University, Napoli, Italy
13 shared publications- Francesca Bisulli
IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member ERN‐EpiCARE Bologna Italy
11 shared publications - Paolo Tinuper
University of Bologna, Bologna, Italy
11 shared publications - Elena Pasini
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
10 shared publications
Latest Publications
- Open Access
- 23 April 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (3) , 1083-1087
A de novo pathogenic variant in MICAL‐1 causes epilepsy with auditory features
Familial epilepsy with auditory features (FEAF), previously known as autosomal-dominant lateral temporal lobe epilepsy (ADLTE) is a genetically heterogeneous syndrome, clinically characterized by focal seizures with prominent auditory symptoms. It is inherited with autosomal-dominant pattern with reduced penetrance (about 70%). Sporadic epilepsy with auditory features cases are more frequent and clinically indistinguishable from familial cases. One causal gene, MICAL-1, encodes MICAL-1, an intracellular multi-domain enzyme that is an important regulator of filamentous actin (F-actin) structures. Pathogenic variants in MICAL-1 account for approximately 7% of FEAF families. Here, we describe a de novo MICAL-1 pathogenic variant, p.Arg915Cys, in a sporadic case, an affected 21-year-old Italian man with no family history of epilepsy. Genetic testing was performed in the patient and his parents, using a next-generation sequencing panel. In cell-based assay, this variant significantly increased MICAL-1 oxidoreductase activity, which likely resulted in dysregulation of F-actin organization. This finding provides further support for a gain-of-function effect underlying MICAL-1-mediated epilepsy pathogenesis, as previously seen with other pathogenic variants. Furthermore, the case study provides evidence that de novo MICAL-1 pathogenic variants can occur in sporadic cases with epilepsy with auditory feature (EAF).
- 23 April 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (3) , 1083-1087
Open AccessA de novo pathogenic variant in MICAL‐1 causes epilepsy with auditory features
Familial epilepsy with auditory features (FEAF), previously known as autosomal-dominant lateral temporal lobe epilepsy (ADLTE) is a genetically heterogeneous syndrome, clinically characterized by focal seizures with prominent auditory symptoms. It is inherited with autosomal-dominant pattern with reduced penetrance (about 70%). Sporadic epilepsy with auditory features cases are more frequent and clinically indistinguishable from familial cases. One causal gene, MICAL-1, encodes MICAL-1, an intracellular multi-domain enzyme that is an important regulator of filamentous actin (F-actin) structures. Pathogenic variants in MICAL-1 account for approximately 7% of FEAF families. Here, we describe a de novo MICAL-1 pathogenic variant, p.Arg915Cys, in a sporadic case, an affected 21-year-old Italian man with no family history of epilepsy. Genetic testing was performed in the patient and his parents, using a next-generation sequencing panel. In cell-based assay, this variant significantly increased MICAL-1 oxidoreductase activity, which likely resulted in dysregulation of F-actin organization. This finding provides further support for a gain-of-function effect underlying MICAL-1-mediated epilepsy pathogenesis, as previously seen with other pathogenic variants. Furthermore, the case study provides evidence that de novo MICAL-1 pathogenic variants can occur in sporadic cases with epilepsy with auditory feature (EAF).
- 27 January 2020
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 20 (3) , 251-269
Advances in genetic testing and optimization of clinical management in children and adults with epilepsy
Introduction: Epileptic disorders are a heterogeneous group of medical conditions with epilepsy as the common denominator. Genetic causes, electro-clinical features, and management significantly vary according to the specific condition. Areas Covered: Relevant diagnostic advances have been achieved thanks to the advent of Next Generation Sequencing (NGS)-based molecular techniques. These revolutionary tools allow to sequence all coding (whole exome sequencing, WES) and non-coding (whole genome sequencing, WGS) regions of human genome, with a potentially huge impact on patient care and scientific research. Expert Opinion: The application of these tests in children and adults with epilepsy has led to the identification of new causative genes, widening the knowledge on the pathophysiology of epilepsy and resulting in therapeutic implications. This review will explore the most recent advancements in genetic testing and provide up-to-date approaches for the choice of the correct test in patients with epilepsy.
- 27 January 2020
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 20 (3) , 251-269
Advances in genetic testing and optimization of clinical management in children and adults with epilepsy
Introduction: Epileptic disorders are a heterogeneous group of medical conditions with epilepsy as the common denominator. Genetic causes, electro-clinical features, and management significantly vary according to the specific condition. Areas Covered: Relevant diagnostic advances have been achieved thanks to the advent of Next Generation Sequencing (NGS)-based molecular techniques. These revolutionary tools allow to sequence all coding (whole exome sequencing, WES) and non-coding (whole genome sequencing, WGS) regions of human genome, with a potentially huge impact on patient care and scientific research. Expert Opinion: The application of these tests in children and adults with epilepsy has led to the identification of new causative genes, widening the knowledge on the pathophysiology of epilepsy and resulting in therapeutic implications. This review will explore the most recent advancements in genetic testing and provide up-to-date approaches for the choice of the correct test in patients with epilepsy.
- 1 July 2018
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 170, 27-33
LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma
- 1 July 2018
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 170, 27-33
LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma
- Open Access
- 1 June 2018
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 4 (3) , e241
Whole-exome sequencing to disentangle the complex genetics of hippocampal sclerosis–temporal lobe epilepsy
Mesial temporal lobe epilepsy with Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is a common epilepsy syndrome accounting for approximately 20% of people with epilepsy.1 It typically shows electroclinical features indicative of seizure onset in the mesial or limbic structures of the temporal lobe, i.e., epigatric/visceral, autonomic, psycho-affective, and sensorial symptoms, including déjà vu.1 Awareness is generally preserved at onset, but loss of consciousness may also occur, with motionless stare and oro-alimentary, vocal, or gestural automatisms, eventually followed by a convulsive seizure. EEGs show anterior or mid-temporal epileptic abnormalities combined with focal slowing. Hippocampal sclerosis (HS) is demonstrable on coronal MRI sequences by a unilateral (or asymmetrical) decrease in hippocampal volume and an increase in signal on T2-weighted sequences. The neuropathologic hallmark of HS is a combination of atrophy and astrogliosis of the amygdala, hippocampus, uncus, parahippocampal gyrus, and the entorhinal cortex.1 The diagnosis of MTLE-HS is crucial because it is often uncontrolled by antiseizure drugs but typically responsive to resective surgery.2,3
- 1 June 2018
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 4 (3) , e241
Open AccessWhole-exome sequencing to disentangle the complex genetics of hippocampal sclerosis–temporal lobe epilepsy
Mesial temporal lobe epilepsy with Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is a common epilepsy syndrome accounting for approximately 20% of people with epilepsy.1 It typically shows electroclinical features indicative of seizure onset in the mesial or limbic structures of the temporal lobe, i.e., epigatric/visceral, autonomic, psycho-affective, and sensorial symptoms, including déjà vu.1 Awareness is generally preserved at onset, but loss of consciousness may also occur, with motionless stare and oro-alimentary, vocal, or gestural automatisms, eventually followed by a convulsive seizure. EEGs show anterior or mid-temporal epileptic abnormalities combined with focal slowing. Hippocampal sclerosis (HS) is demonstrable on coronal MRI sequences by a unilateral (or asymmetrical) decrease in hippocampal volume and an increase in signal on T2-weighted sequences. The neuropathologic hallmark of HS is a combination of atrophy and astrogliosis of the amygdala, hippocampus, uncus, parahippocampal gyrus, and the entorhinal cortex.1 The diagnosis of MTLE-HS is crucial because it is often uncontrolled by antiseizure drugs but typically responsive to resective surgery.2,3
- 1 June 2018
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (6) , 493-495
The genetic basis of juvenile myoclonic epilepsy
- 1 June 2018
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (6) , 493-495
The genetic basis of juvenile myoclonic epilepsy
- 13 March 2018
- Published by Wiley in Annals of Neurology
- Vol. 83 (3) , 483-493
Mutations in MICAL‐1cause autosomal‐dominant lateral temporal epilepsy
Objective: Autosomal‐dominant lateral temporal epilepsy (ADLTE) is a genetic focal epilepsy characterized by auditory symptoms. Two genes, LGI1 and RELN, encoding secreted proteins, are implicated in the etiology of ADLTE, but half of the affected families remain genetically unsolved, and the underlying molecular mechanisms are yet to be clarified. We aimed to identify additional genes causing ADLTE to better understand the genetic basis and molecular pathway underlying this epileptic disorder.Methods: A cohort of Italian ADLTE families was examined by whole exome sequencing combined with genome‐wide single‐nucleotide polymorphism‐array linkage analysis.Results: We identified two ADLTE‐causing variants in the MICAL‐1 gene: a p.Gly150Ser substitution occurring in the enzymatically active monooxygenase (MO) domain and a p.Ala1065fs frameshift indel in the C‐terminal domain, which inhibits the oxidoreductase activity of the MO domain. Each variant segregated with ADLTE in a single family. Examination of candidate variants in additional genes excluded their implication in ADLTE. In cell‐based assays, both variants significantly increased MICAL‐1 oxidoreductase activity and induced cell contraction in COS7 cells, which likely resulted from deregulation of F‐actin dynamics.Interpretation: MICAL‐1 oxidoreductase activity induces disassembly of actin filaments, thereby regulating the organization of the actin cytoskeleton in developing and adult neurons and in other cell types. This suggests that dysregulation of the actin cytoskeleton dynamics is a likely mechanism by which MICAL‐1 pathogenic variants lead to ADLTE. Ann Neurol 2018;83:483–493
- 13 March 2018
- Published by Wiley in Annals of Neurology
- Vol. 83 (3) , 483-493
Mutations in MICAL‐1cause autosomal‐dominant lateral temporal epilepsy
Objective: Autosomal‐dominant lateral temporal epilepsy (ADLTE) is a genetic focal epilepsy characterized by auditory symptoms. Two genes, LGI1 and RELN, encoding secreted proteins, are implicated in the etiology of ADLTE, but half of the affected families remain genetically unsolved, and the underlying molecular mechanisms are yet to be clarified. We aimed to identify additional genes causing ADLTE to better understand the genetic basis and molecular pathway underlying this epileptic disorder.Methods: A cohort of Italian ADLTE families was examined by whole exome sequencing combined with genome‐wide single‐nucleotide polymorphism‐array linkage analysis.Results: We identified two ADLTE‐causing variants in the MICAL‐1 gene: a p.Gly150Ser substitution occurring in the enzymatically active monooxygenase (MO) domain and a p.Ala1065fs frameshift indel in the C‐terminal domain, which inhibits the oxidoreductase activity of the MO domain. Each variant segregated with ADLTE in a single family. Examination of candidate variants in additional genes excluded their implication in ADLTE. In cell‐based assays, both variants significantly increased MICAL‐1 oxidoreductase activity and induced cell contraction in COS7 cells, which likely resulted from deregulation of F‐actin dynamics.Interpretation: MICAL‐1 oxidoreductase activity induces disassembly of actin filaments, thereby regulating the organization of the actin cytoskeleton in developing and adult neurons and in other cell types. This suggests that dysregulation of the actin cytoskeleton dynamics is a likely mechanism by which MICAL‐1 pathogenic variants lead to ADLTE. Ann Neurol 2018;83:483–493
- 1 January 2018
- Published by Elsevier in Epilepsy Research
- Vol. 139, 51-53
CNTNAP2 mutations and autosomal dominant epilepsy with auditory features
- 1 January 2018
- Published by Elsevier in Epilepsy Research
- Vol. 139, 51-53
CNTNAP2 mutations and autosomal dominant epilepsy with auditory features
- Open Access
- 1 March 2017
- Published by Elsevier in Epilepsy & Behavior
- Vol. 68, 103-107
The clinical phenotype of autosomal dominant lateral temporal lobe epilepsy related to reelin mutations
- 1 March 2017
- Published by Elsevier in Epilepsy & Behavior
- Vol. 68, 103-107
Open AccessThe clinical phenotype of autosomal dominant lateral temporal lobe epilepsy related to reelin mutations
- Open Access
- 19 October 2016
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 12 (10) , e1006376
Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors
Autosomal dominant lateral temporal epilepsy (ADTLE) is a focal epilepsy syndrome caused by mutations in the LGI1 gene, which encodes a secreted protein. Most ADLTE-causing mutations inhibit LGI1 protein secretion, and only a few secretion-positive missense mutations have been reported. Here we describe the effects of four disease-causing nonsynonymous LGI1 mutations, T380A, R407C, S473L, and R474Q, on protein secretion and extracellular interactions. Expression of LGI1 mutant proteins in cultured cells shows that these mutations do not inhibit protein secretion. This finding likely results from the lack of effects of these mutations on LGI1 protein folding, as suggested by 3D protein modelling. In addition, immunofluorescence and co-immunoprecipitation experiments reveal that all four mutations significantly impair interaction of LGI1 with the ADAM22 and ADAM23 receptors on the cell surface. These results support the existence of a second mechanism, alternative to inhibition of protein secretion, by which ADLTE-causing LGI1 mutations exert their loss-of-function effect extracellularly, and suggest that interactions of LGI1 with both ADAM22 and ADAM23 play an important role in the molecular mechanisms leading to ADLTE. Temporal lobe epilepsy is the most common form of focal epilepsy. It is frequently associated with structural brain abnormalities, but genetic forms caused by mutations in major genes have also been described. Autosomal dominant lateral temporal epilepsy (ADLTE) is a familial condition characterized by focal seizures with prominent auditory symptoms. ADLTE-causing mutations are found in the LGI1 gene in about 30% of affected families. LGI1 encodes a protein, LGI1, that is secreted by neurons. Most LGI1 mutations suppress protein secretion, thereby preventing protein function in the extracellular environment. In this paper, we examine the effects of four LGI1 mutations and show that they do not inhibit secretion of the LGI1 protein but impair its interaction with the neuronal receptors ADAM22 and ADAM23. In agreement with these findings, a three- dimensional model of the protein predicts that these mutations have no impact on LGI1 structure but instead may affect amino acids that are critical for interactions with ADAM receptors. Our results provide novel evidence for an extracellular mechanism through which mutant LGI1 proteins cause ADLTE and strengthen the importance of LGI1-ADAM22/23 protein complex in the mechanisms underlying ADLTE.
- 19 October 2016
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 12 (10) , e1006376
Open AccessSecretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors
Autosomal dominant lateral temporal epilepsy (ADTLE) is a focal epilepsy syndrome caused by mutations in the LGI1 gene, which encodes a secreted protein. Most ADLTE-causing mutations inhibit LGI1 protein secretion, and only a few secretion-positive missense mutations have been reported. Here we describe the effects of four disease-causing nonsynonymous LGI1 mutations, T380A, R407C, S473L, and R474Q, on protein secretion and extracellular interactions. Expression of LGI1 mutant proteins in cultured cells shows that these mutations do not inhibit protein secretion. This finding likely results from the lack of effects of these mutations on LGI1 protein folding, as suggested by 3D protein modelling. In addition, immunofluorescence and co-immunoprecipitation experiments reveal that all four mutations significantly impair interaction of LGI1 with the ADAM22 and ADAM23 receptors on the cell surface. These results support the existence of a second mechanism, alternative to inhibition of protein secretion, by which ADLTE-causing LGI1 mutations exert their loss-of-function effect extracellularly, and suggest that interactions of LGI1 with both ADAM22 and ADAM23 play an important role in the molecular mechanisms leading to ADLTE. Temporal lobe epilepsy is the most common form of focal epilepsy. It is frequently associated with structural brain abnormalities, but genetic forms caused by mutations in major genes have also been described. Autosomal dominant lateral temporal epilepsy (ADLTE) is a familial condition characterized by focal seizures with prominent auditory symptoms. ADLTE-causing mutations are found in the LGI1 gene in about 30% of affected families. LGI1 encodes a protein, LGI1, that is secreted by neurons. Most LGI1 mutations suppress protein secretion, thereby preventing protein function in the extracellular environment. In this paper, we examine the effects of four LGI1 mutations and show that they do not inhibit secretion of the LGI1 protein but impair its interaction with the neuronal receptors ADAM22 and ADAM23. In agreement with these findings, a three- dimensional model of the protein predicts that these mutations have no impact on LGI1 structure but instead may affect amino acids that are critical for interactions with ADAM receptors. Our results provide novel evidence for an extracellular mechanism through which mutant LGI1 proteins cause ADLTE and strengthen the importance of LGI1-ADAM22/23 protein complex in the mechanisms underlying ADLTE.